Director, Thought Leader Strategy, I/O Commercial Franchise
Coherus Oncology
This listing was originally posted on Coherus Oncology's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Drug products linked to this role
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moOverview:
The Director, Thought Leader Strategy, I/O Commercial Franchise, will develop advocacy with key stakeholders and KOLs within the head and neck cancer space, to support the continued success of LOQTORZI®. This role will be responsible for supporting in-line brand marketing initiatives for LOQTORZI and will report to the Senior Director, I/O Brand Marketing.
Responsibilities:
Qualifications:
The Base Salary Range for this position is $190,000 to $240,000. Coherus considers various factors, including professional background and work experience, when determining base pay. These considerations mean actual compensation will vary.
Coherus provides equal employment opportunities to all employees and applicants for employment and prohibits unlawful discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws. We also prohibit discrimination based on the perception that anyone has any of these characteristics or is associated with a person who has or is perceived as having any of these characteristics.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at Coherus Oncology?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Biologics, Biosimilars
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo